The Nantes University Hospital has announced the launch of a clinical trial evaluating the performance and safety of the NEOmom® Gastric Video Capsule for detecting gastric cancer. This trial proposes a significant step forward, introducing magnetically controlled video capsule endoscopy (MC-VCE) technology to optimize gastric cancer diagnosis non-invasively. The study is scheduled to begin in January 2026.
In this article:
- What changed?
- What is the device?
- Clinical trial design and timelines
- Who benefits?
- FAQ
- Conclusion
- Disclaimer
- Announcement link
What changed?
In recent years, gastric cancer screening methods have advanced, but many traditional approaches remain invasive and uncomfortable for patients. The introduction of magnetically controlled video capsule endoscopy (MC-VCE) offers a safer and less invasive alternative. The NEOmom® Gastric Video Capsule trial is expected to assess how effectively this device identifies abnormalities in the stomach lining that may indicate malignancy. Nantes University Hospital, the sponsor of the trial, aims to contribute key data to modernize diagnostic tools for this condition.
What is the device?
The NEOmom® Gastric Video Capsule is a magnetically controlled endoscopic device designed to examine the stomach without traditional insertion methods such as esophagogastroduodenoscopy. Once swallowed, the capsule provides high-resolution video images of the gastric lining. Magnetically controlled technology enables clinicians to guide the capsule in real time, optimizing visualization while maintaining patient comfort.
Clinical trial design and timelines
Objectives
The primary objective of the trial is to evaluate the accuracy of MC-VCE in detecting gastric cancer compared to conventional diagnostic procedures. Secondary objectives include assessing patient comfort and procedural safety.
Methodology
The trial will follow a prospective comparative design involving patients under endoscopic investigation for stomach-related conditions. Data on imaging quality, diagnostic accuracy, and patient feedback will be collected and analyzed.
Start date and recruitment status
Recruitment is planned to commence on January 10, 2026. Participants may inquire at Nantes University Hospital about eligibility criteria once recruitment officially begins.
Who benefits?
Patients undergoing screening for gastric cancer or related conditions could experience greater comfort using non-invasive MC-VCE technology. Healthcare providers will gain an innovative diagnostic tool to enhance procedural efficiency and outcomes. Regulatory professionals and device manufacturers may use outcomes from this study to support ongoing innovation and compliance in medical device development.
FAQ
1. What makes MC-VCE unique?
Unlike traditional methods, MC-VCE allows for non-invasive gastric lining inspection, with minimized patient discomfort and efficient imaging control through magnetic technology.
2. When can patients participate?
The trial will begin its recruitment phase in January 2026. Updates on enrollment will likely follow closer to the date.
3. How will the trial outcomes affect medical practice?
Outcomes will establish the performance of MC-VCE compared to current methods, paving the way for broader adoption in medical settings if successful.
Conclusion
The upcoming trial of the NEOmom® Gastric Video Capsule represents a promising advancement in the field of gastric cancer diagnostics. By introducing magnetically controlled technology, healthcare professionals may soon find new tools to enhance patient comfort, procedural safety, and diagnostic accuracy. Stay tuned for updates as the trial progresses.
Disclaimer
The information above is intended for healthcare and regulatory professionals. It does not constitute legal or medical advice. For precise guidelines, consult official sources or regulatory authorities directly.
Announcement link
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07323186?term=medical+device